Tyzavan is supplied as a single-dose bag in 7 presentations allowing for dosing flexibility. Tyzavan ™ (vancomycin injection), a ready-to-infuse, room temperature stable formulation of vancomycin, is ...

LONDON, Dec. 8, 2025 /PRNewswire/ — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces the launch of the first-of-its-kind, ready-to-use vancomycin premix ...

TYZAVAN ™ is a glycopeptide antibacterial indicated for the treatment of the following infections in adult and pediatric patients (1 month and older) for whom appropriate dosing with this formulation ...

Ready-to-use sepsis therapy marks new advancement in time-critical treatment LONDON, Dec. 8, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today ...

Guidelines recommend against use of midline catheters for vancomycin-based outpatient parenteral antimicrobial therapy (OPAT), but evidence supporting the guidance is limited. This retrospective study ...

Hikma has obtained permission from the Food and Drug Administration for a novel formulation of the first-of-its-kind, ready-to-infuse formulation of vancomycin, under the brand name Tyzavan ...

C. difficile infection recurrence rates were numerically lower with vancomycin than with placebo, though the difference was not significant. However, the results could be clinically meaningful, an ...

Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today ...

LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to ...